1. Field of the Invention
The present invention relates to a method and apparatus for performing assays; and more particularly relates to a method and apparatus for performing chemical, biological or biochemical assays using microfluidic technology.
2. Brief Description of Related Art
One of the primary factors affecting the data quality of a multiplexed system is biological cross reactivity, which is caused when multiple analytes and a multi-reagent detection cocktail are mixed in a single reaction vessel. For example, in a protein assay, the mixing of analytes (proteins) and the detection cocktail (labeled antibodies) can result in unintended secondary cross-reactions or interference that distort the measurements and severely compromise data quality. This biological cross reactivity can be mitigated by attempting to design the assay with components that do not negatively react; however, this becomes increasingly impractical and difficult (due to the high number of variables introduced) as the multiplex level increases. Moreover, even for sets of antibodies in the assay with components that do not negatively react, the multiplexed result is still typically relative to the performance of any one of the individual components, due to the application of a common assay buffer across all of the antibodies, which is typically not the optimal buffer with respect to pH, salinity, etc for each of the antibodies.
The present invention provides a new and unique method and apparatus for performing a chemical, biochemical, or biological assay on a sample, including a biological assay, e.g., on a patient sample, such as serum, plasma, cerebrospinal fluid, urine, blood, etc.
According to some embodiments of the present invention, the apparatus may take the form of an assay device or apparatus comprising: a microfluidic assay cartridge or device that contains at least one sample inlet well configured to receive a sample; and a microfluidic sub-unit associated with the microfluidic assay cartridge and comprising microfluidic channels, micro-valves and at least one separate and fluidicly isolated isolation channel, and at least one hollow element, e.g. including at least one hollow glass cylinder, tube or particle. The at least one hollow element may be functionalized with a capture moiety or molecules so as to form at least one reaction vessel. The microfluidic channels and micro-valves may be configured to respond to signaling containing information about performing the assay and to controllably receive the sample and at least one reagent in the at least one reaction vessel, and to provide from the at least one reaction vessel light containing information about the assay performed on the sample inside the at least one reaction vessel as a result of said at least one reagent.
By way of example, the microfluidic channels and micro-valves may also be configured to respond to the signaling containing information about performing the assay and to introduce into the at least one reaction vessel some combination of the following:
where the at least one reaction vessel may be configured to allow chemical reactions to take place for performing the assay, and to provide emitted light containing information about the assay performed to be interrogated, based at least partly on the signalling received.
According to some embodiments, the present invention may comprise one or more of the following features: The microfluidic sub-unit may be configured to contain on-board the assay reagents, including the plurality of reagents, such as labeled antibodies, to contain on-board the reagents such as an enzymatic substrate for producing the emitted light signal, and/or on-board the wash solution to remove any non-specifically bound proteins or antibodies. These microfluidic sub units may also be configured such that the on-board reagents, such as those defined above, are contained in a dehydrated form, and are rehydrated by control signals to the microfluidic system that introduces buffer fluids to the said dehydrated reagents. Embodiments are also envisioned in which the assay reagents, the enzymatic substrate or wash solution are not contained on-board, but instead form part of another device, apparatus or equipment and provided to the assay device or apparatus. The apparatus may be configured with at least one common on-board waste receptacle or individual on-board waste receptacles that are configured to capture the wash solution, along with non-specifically bound proteins or antibodies. The microfluidic assay cartridge may be configured to be disposable. The apparatus may comprise a detection system configured to respond to the emitted light signal provided from at least one reaction vessel, and provide a signal containing information about the assay performed in relation to the at least one reaction vessel. The apparatus may comprise a controller configured to execute a computer program code and to provide the signaling to the microfluidic channels and micro-valves in order to perform the assay. Each of the series of microfluidic channels may be configured to correspond to a respective one of the at least one sample inlet well. Embodiments for some assays are also envisioned in which the wash is optional, and only the assay reagents and the enzymatic substrate are introduced, but not the wash. The at least one reaction vessel may be contained in a channel that may be configured to conduct independent assays, where the channel may be understood to be separate and fluidicly-isolated from other channels so as to substantially eliminate cross reactivity between the assays performed in the respective channels. The at least one reaction vessel contained in each isolation channel may be functionalized with the same capture moiety or capture molecules; or the at least one reaction vessel contained in each isolation channel may be each functionalized with a different capture moiety or capture molecules; or some combination thereof. The at least one hollow element may be configured as a honeycomb with multiple axial cavities or chambers. The at least one reagent may comprises a plurality of reagents.
According to some embodiments of the present invention, the apparatus may take the form of a controller that may be configured to control the performance of an assay by an assay device comprising a microfluidic assay cartridge that contains at least one sample inlet well configured to receive a sample; and a microfluidic sub-unit associated with the microfluidic assay cartridge and comprising microfluidic channels, micro-valves and at least one hollow element, the at least one hollow element being functionalized with a capture moiety or molecules so as to form at least one reaction vessel.
In this embodiment, the controller may comprise:
at least one processor and at least one memory device, including computer program code; the at least one memory device and the computer program code may be configured, with the at least one processor, to cause the controller at least to provide signalling containing information about performing the biological assay to the microfluidic channels and micro-valves, where the microfluidic channels and micro-valves are configured to respond to the signaling, to direct the sample from the at least one sample inlet well to the at least one reaction vessel, and to introduce into the at least one reaction vessel at least one reagent, so as to provide from the at least one reaction vessel light containing information about the assay performed on the sample inside the at least one reaction vessel as a result of the at least one reagent.
According to some embodiments, the present invention may also take the form of a method for performing the assay process using a new and unique separation technique consistent with that set forth above. The method may be implemented by providing the means set forth above for automatically separating components where negative cross reactions may occur, and by employing the microfluidic assay cartridge or device that will automate some of the manual steps typically associated with these types of tests. The separation technique set forth herein for performing the assay process will substantially minimize the need to design around cross reactivity. By way of example, the method may comprise some combination of the following:
According to some embodiments, the present invention may also take the form of an apparatus consistent with that described above, but where the microfluidic channels are configured to respond to a control impulse containing information about performing the assay and to receive the sample and at least one reagent in the reaction vessel. By way of example, the control impulse may take the form of at least one control signal that causes pneumatic control lines to open or close micro-valves arranged in relation to the microchannel that causes the sample and the at least one reagent to flow into the at least one reaction vessel in order to perform the assay; or alternatively that causes a device arranged in relation to the microchannel to provide positive or negative pressure in the microchannel that causes the sample and the at least one reagent to flow into the at least one reaction vessel in order to perform the assay.
Embodiments are also envisioned within the spirit of the present invention in which, instead of using at least one hollow element having a capture moiety or molecules, one may use encoded or non-encoded microparticles having an outside surface functionalized, e.g. by coating, with the capture moiety or molecules, consistent with that disclosed in Ser. No. 12/945,459, filed 12 Nov. 2010, which is hereby incorporated by reference in its entirety.
The present invention employs a novel reaction vessel that, in and of itself, enables very low cost manufacturing, fast reaction time, low sample volume, high sensitivity, and large dynamic range. The novel hollow reaction vessel may take the form of the at least one hollow element that has been functionalized with the capture moiety or capture molecules.
Advantages of embodiments of the present invention include substantially minimizing the need to design around cross reactivity by providing a means for automatically separating components where negative cross reactions occur. Additionally, this assay device will improve ease of use by employing a disposable microfluidic assay cartridge that will automate some of the manual steps typically associated with these types of tests. This assay device will optimize buffer conditions to produce independently optimized assays. The optimized buffer conditions may include optimizing in relation to the pH, salinity or both. This assay device will also allow samples to be independently diluted with buffer solution with respect to each channel.
It is the purpose of the present invention to deliver an apparatus or a method that provides multi-sample, multiplex assays with data quality that is significantly improved over current methods while at the same time providing greater ease of use.
The drawing, which are not necessarily drawn to scale, includes the following Figures:
a(1) shows an example of a 4-plex architecture with independent pump control and individual waste reservoirs according to some embodiments of the present invention;
In
The microfluidic sub-unit (3) contains a series of microfluidic channels and micro-valves (4) that direct a sample, including a patient sample, such as serum, plasma, cerebrospinal fluid, urine, blood, etc., from the at least one sample inlet well (2) to separate and fluidicly-isolated channels (5) that contain one or more reaction vessels (19), which have been functionalized with a capture moiety or capture molecules such as antibodies, antigens, or oligomers, as shown in
The biological reactions take place inside at least one hollow element (14) which has been functionalized with a capture moiety or molecules (15), so as to form the reaction vessel (19). By way of example, the at least one hollow element (14) may be configured or fabricated by drawing glass tubing with an outer diameter and an inner diameter, and cutting or dicing it, e.g., with a dicing saw. The at least one hollow element (14) may also be configured or fabricated by etching out the core of commercially available high NA fused silica optical fibers or rods, which provide extremely high optical quality at a very low cost. The present invention is described by way of example with the at least one hollow element (14) being made of glass; however, the scope of the invention is intended to include making the at least one hollow element (14) from other types or kind of material either now known or later developed in the future, including other types or kinds of non-glass materials. The at least one hollow element (14) may be suspended in a housing (16) with a significant amount of air space (17) surrounding the outside diameter of the at least one hollow element (14). This air space (17) provides the large confocal zone (18) by providing an area that is free from any introduced background fluorescence. The at least one hollow element (14) may be installed with a press or friction fit into and received by walls of the housing (16), which is described in further detail below, that will direct the sample through the inside diameter of the at least one hollow element (14), and prevent the sample from entering the air space (17) surrounding the at least one hollow element (14). The at least one hollow element (14) may be configured or designed with a cavity or chamber having a very small inside diameter (e.g., approximately 10 μm inner diameter (ID)) and a length-to-I.D. aspect ratio of, e.g., approximately 20:1 (approximately 200 μm L). This configuration provides the reaction vessel (19) with a very high surface area-to-volume ratio, which in-turn drives fast reaction kinetics. In addition, the effect of the sample being forced through a very low volume reaction vessel increases the probability of a binding event because a higher proportion of the sample comes in contact with the functionalized surface of the hollow element, thereby increasing sensitivity. In
As shown in
In an alternate embodiment of this invention, a plurality of hollow elements (14) of decreasing inside diameters can be functionalized and placed in-line to address varying analyte densities, prevent oversaturation, and extend the dynamic range of the systems analysis capabilities. Alternatively, a plurality of hollow elements of the same diameter that have been functionalized with different loading densities of the capture moiety or molecules can be placed in-line to address varying analyte densities, prevent over saturation, and extend the dynamic range. It is also envisioned that combinations of the above configuration can be employed to achieve optimized results.
The scope of the invention is not intended to be limited to any particular type or kind of sample that forms part of the assay process, and is intended to include samples of substance both now known and later developed in the future.
In
In
In
The apparatus may also include a controller (140) for implementing the functionality associated with the assay performed by the microfluidic sub-unit (3) embedded within the disposable microfluidic assay cartridge or device (1). The controller (140) may be configured to execute a computer program code and to provide the signaling along signal paths, e.g., S0, S1, S2, S3, S4, S5, S6, . . . , S10 to each microfluidic channel (8) and/or micro-valves (4, 9) in order to perform the assay. In operation, the controller (140) may be configured to execute the computer program code and to exchange signaling along signal path S7 with the detection system (13), including receiving a detection system signal containing information about the reactions taking place in the reaction vessels (19) being interrogated by the detection system (13). The controller (140) may also be configured to receive an input signal(s) along signal path Sin, and to provide an output signal(s) along signal path Sout. By way of example, the output signal along signal path Sout may contain either the raw detection system signal containing information about the reactions taking place in the reaction vessels (19) being interrogated by the detection system (13), or a processed detection system signal containing information about the reactions taking place in the reaction vessels (19) being interrogated by the detection system (13). By way of example, the input signal along signal path Sin may contain information to control or modify the functionality of the controller (140), including a signal requesting the provisioning of the output signal along signal path Sout. The scope of the invention is not intended to be limited to the type or kind of information being provided to or received by the controller (140) via the input signal along signal path Sin or the type or kind of information being provided from the controller (140) via the output signal along signal path Sout either now known or later developed in the future. Further, by way of example, the controller (140) may be implemented using hardware, software, firmware, or a combination thereof. In a typical software implementation, the controller (140) would include one or more microprocessor-based architectures having a processor or microprocessor, memory such as a random access memory (RAM) and/or a read only memory (ROM), input/output devices and control, data and address buses connecting the same. A person skilled in the art would be able to program such a microcontroller or microprocessor-based implementation with the computer program code to perform the functionality described herein without undue experimentation. The scope of the invention is not intended to be limited to any particular microprocessor-based architecture implementation using technology either now known or later developed in the future.
Embodiments are envisioned in which the controller (140) either is on-board and forms part of the apparatus (50), or is not on-board but forms part of another apparatus, device, system or equipment that cooperates with the apparatus (50) in relation to implementing the assay process with the microfluidic technology disclosed herein.
In
By way of example, the micro-valves (4, 4a, 9), isolation channels (5), detection system (13), along with other components or devices shown and described herein in relation to
The present invention is described by way of using micro-valves configured to control the flow of one or more of the sample, the assay reagents (7), the substrate (10) and the wash (13) into the at least one separate and fluidicly-isolated isolation channels (5). However, the scope of the invention is intended to include using other types or kind of techniques either now known or later developed in the future to control the flow of one or more of the sample, the assay reagents (7), the substrate (10) and the wash (13) into the at least one separate and fluidicly-isolated isolation channels (5), e.g., such as by using a configuration to provide positive pressure to push and cause the flow of one or more of the sample, the assay reagents (7), the substrate (10) and the wash (13) into the at least one separate and fluidicly-isolated isolation channels (5), or such as by using a configuration to provide negative pressure (e.g. a vacuum) to pull (or draw) and cause the flow of one or more of the sample, the assay reagents (7), the substrate (10) and the wash (13) into the at least one separate and fluidicly-isolated isolation channels (5), or such as by using some combination of pushing and/or pulling to cause the flow of one or more of the sample, the assay reagents (7), the substrate (10) and the wash (13) into the at least one separate and fluidicly-isolated isolation channels (5). The configuration to provide positive pressure may be configured on the upper end (as shown in
By way of example, the process of conducting an immunoassay in a cartridge according to the present invention using a sandwich enzyme-linked immunosorbent assay (ELISA) may entail some combination of the following:
Step 1: A capture antibody specific for the target analyte of interest is chemically cross-linked onto the surface of the hollow element (14) in
Step 2: The reaction vessel (19) once placed into the isolation channel (5) is then ready to receive the patient sample (serum, plasma, cerebrospinal fluid, urine, blood, etc).
Step 3: A precise volume of the patient sample is then introduced by flowing the material into the reaction vessel (19), either, e.g., by positive or negative pressure, during which time the target analyte of interest is retained by virtue of specific binding to the capture antibody coated onto the interior surface of the reaction vessel (19).
Step 4: The reaction vessel (19) is then rinsed with a buffer to wash away the unbound protein.
Step 5: The second antibody, referred to as a detection antibody since it is coupled to a fluorescent tag capable of emitting a light signal, is then is flowed into the reaction vessel (19) whereupon it binds to the target analyte retained on the interior surface via the capture antibody.
Step 5a: An alternative embodiment of this process may be to use a second antibody without a fluorescent conjugate, and then to add the fluorescent conjugate in a subsequent step. Note that this may also include an additional rinse step prior to adding the fluorescent conjugate.
Step 6: The reaction vessel (19) is then rinsed again with a buffer to remove unbound protein, and the excess fluorescent tag.
Step 7: The amount of the target analyte captured is then quantified by the amount of fluorescent light emitted by the detection antibody as a result of irradiating the fluorescent chemical tag with the appropriate excitation wavelength onto the reaction vessel (19).
Step 8: The amount of analyte within the reaction vessel (19) is proportional to the amount of light emitted by the detection antibody fluorescent tag, and hence is directly proportional to the amount of analyte within the patient sample.
The controller (140) shown in
The scope of the invention is described by way of example using the sandwich ELISA biological assay technique. However, the scope of the invention is not intended to be limited to using the sandwich ELISA biological assay technique, e.g., embodiments are also envisioned using other types or kind of biological assay techniques either now known or later developed in the future, including an “indirect” ELISA, a competitive ELISA, a reverse ELISA, as well as other non-ELISA techniques.
By way of example,
a shows examples of a square channel, a partially filled channel and a pneumatic channel.
In some embodiments, the channel may be partially filled with Polydimethylsiloxane (PDMS) fillet to form a conformal surface for a membrane seal, configured to engage an outer surface of the hollow element (14). See
PDMS is a material that belongs to a group of polymeric organosilicon compounds that are commonly referred to as silicones. PDMS material doesn't fluoresce which is important in processing the light signal received back from the reaction vessel (19).
e(1) and 3e(2) show the hollow element (14) fit within walls W1, W2 of the housing (16) that forms part of the isolation channel (5). See
f(1) and 3(f)2 show the hollow element (14) fit within walls W1, W2 of the housing (16) that forms part of the isolation channel (5) with fill. See
In
By way of example,
By way of example,
By way of example,
By way of example,
The present invention may also take the form of a method for performing the assay process using a new and unique separation technique consistent with that set forth above. The method may be implemented by providing the means set forth above for automatically separating components where negative cross reactions occur, and by employing the disposable microfluidic assay cartridge that will automate some of the manual steps typically associated with these types of tests. The separation technique set forth herein for performing the assay process will eliminate the need to design around cross reactivity.
By way of example, the method for performing an assay may be implemented using the microfluidic technology in
providing a microfluidic assay cartridge (1) that contains at least one sample inlet well (2) configured to receive a sample; and a microfluidic sub-unit (3) associated with the microfluidic assay cartridge (1) and configured to controllably receive the sample from the microfluidic assay cartridge (1); the microfluidic sub-unit (3) comprising microfluidic channels (8), micro-valves (4, 4a, 9), and at least one separate and fluidicly isolated isolation channel (5), and at least one reaction vessel (19), the reaction vessel (19)) comprising at least one hollow element (14) which has been functionalized with a capture moiety or capture molecules (15);
responding to signaling containing information about performing the assay with the microfluidic channels (8) and micro-valves (4, 9), and controllably receiving the sample and the at least one reagent in the at least one reaction vessel (19), so as to provide light containing information about the assay performed on the sample inside the at least one hollow element (14) as a result of the at least one reagent.
The method may also comprise responding to the signaling containing information about performing the assay with the microfluidic channels (8) and micro-valves (4, 9) and introducing into the reaction vessel (19) the following:
allowing with the at least one reaction vessel (19) chemical reactions to take place for performing the assay, and providing the emitted light containing information about the assay performed to be interrogated, e.g. by the detection system (13).
Further, by way of example, the method for performing an assay may also be implemented using the microfluidic technology in
Furthermore, by way of example, the method for performing a biological assay may also be implemented using the steps set forth above, including those set forth in relation to
Many different types and kinds of assays may be performed using the present invention, including a chemical assay or a biological assay.
For example, a singular and multiplexed biological assay may be performed by using at least one functionalized hollow glass cylinder, tube or particle (14) in different isolation channel (5), by using multiple functionalized hollow glass cylinders, tubes or particles (14) in the same isolation channel (5), or by using multiple functionalized hollow glass cylinders, tubes or particles (14) in multiple isolation channels (5).
Further, a multiplexed biological assay may be performed by using multiple reaction vessels, each with different concentrations of capture molecules, all located in a single isolation channel. For example, a first isolation channel C1 may include three reaction vessels, one with a low concentration of capture molecules immobilized on it, a second reaction vessel with a higher concentration of capture molecules immobilized on it, and third reaction vessel with an even higher concentration of capture molecules immobilized on it. A second isolation channel could include reaction vessels with the same range of capture concentrations or a completely different range of capture concentrations or a set of reaction vessels with all of the same reaction concentration. Further, a multiplexed biological assay may be performed by using multiple reaction vessels, each with different inner diameters, all located in the same isolation channel. For example, a first isolation channel C1 may include three reaction vessels, one with a small inside diameter and surface area, a second reaction vessel with a larger inside diameter and surface area, and third reaction vessel with an even larger inside diameter and surface area, so as to introduce different reaction kinetics. A second isolation channel C2 could contain the same set of reaction vessels with the same range of inner diameters or contain a completely different set of reaction vessels with a different range of inner diameters or with all of the same diameters.
Further still, a multiplexed biological assay may be performed by using positive and negative controls. For example, a first isolation channel C1 may include using a positive control, and a negative control while a second isolation channel C2 may also include using a positive and negative control that shouldn't react. Besides, biological assays with +/− controls may include using functionalized hollow glass cylinders, tubes or particles (14) having different antibodies, where the + control spikes and the − control does not react, but can be used, e.g., to gain information about background fluorescents.
Further still, a multiplexed biological assay may be performed by using different channels having different numbers of analytes, e.g., a first isolation channel C1 may include a first number of analytes (e.g. 1), a second isolation channel C2 may include a second number of analytes (e.g. 3), and a third isolation channel C3 may include a third number of analytes, . . . , an Nth isolation channel has an Nth number of analytes.
Further still, a multiplexed biological assay may be performed by using different isolation channels having different biological assays. For example, a first isolation channel C1 may include a first biological assay A, a second isolation channel C2 may include a second biological assay B, and a third isolation channel C3 may include a third biological assay A+B, so that channels can be looked at individually and together, which the channel B biological assay and the channel A+B biological assay can be used to provide further information about the channel A biological assay.
In summary, the present invention affords the possibility of a broad range of hybrid (or conventional) multiplex concepts, including (1) multiple reaction vessels in the same isolation channel, functionalized with different loading densities to extend the dynamic range; (2) multiple reaction vessels with different inner diameters, in the same isolation channel, to introduce different reaction kinetics; (3) multiple reaction vessels having positive and negative controlled reaction vessels in the same isolation channel; (4) multiple reaction vessels with different capture moieties in the same isolation channel, for the purpose of providing a multiplexed (conventional) reaction; and (5) multiple reaction vessels to conduct monoplex and multiplex reactions so that the results may be compared.
The scope of the invention is also intended to include other types or kinds of assays, including a chemical assay or a biological assay, either now known or later developed in the future.
In
c(1) and 7c(2) show the real-time signal evolution due to binding of secondary Ab (IL6) to previously captured antigen inside 3 embedded reaction vessels, and fluorescence images of three embedded reaction vessels taken 15 minutes after flowing detection Ab through the isolation channel and the embedded reaction vessel.
d shows dose response curves for an IL6 sandwich assay performed on the reaction vessels in batch mode. Each data point represents a subset of reaction vessels, take from the same original batch of reaction vessels, but mixed with different IL6 antigen concentrations ranging from 0 pg/ml to 100,000 pg/ml. Clearly shown is the response to the changing concentration of antigen. This batch mode process would be used to both characterize a particular set of reaction vessels and verify the quality of the batch on the very inexpensive component.
Advantages of embedded reaction vessels include the following:
(1) Reaction vessels are made by dicing long strands of hollow glass tubing with the preferred outer and inner dimension into short sections of approximately 100-500 um long.
(2) Because the glass starting material is made with optical fiber manufacturing process, which have been highly optimized over the last 2 decades, and diced with precision diamond cutting machines, dimension control of the reaction vessels are quite excellent.
(3) Because the inside of the reaction vessel is functionalized in a batch process, meaning that up to 1000's of vessels at once are coated with the same solution of Ab, tight statistical control of the active binding moiety can be achieved.
(4) Large batches of reaction vessels means that stringent quality control and characterization of the active element of the biological assay can be performed at very low cost and with high statistical significance.
(5) The inside of the reaction vessels is protected by the outside surface which enables facile and robust techniques for picking up and placing the reaction vessels into the isolation channels without risk of damaging the fragile surface.
By way of example, the term “microfluidics” is generally understood to mean or deal with the behavior, precise control and manipulation of fluids that are geometrically constrained to a small, typically sub-millimeter, scale. In the present application, the microfluidic technology described herein is intended to include technology dimensioned in a range of about 20 micron to about 1000 microns, although the scope of the invention is not intended to be limited to any particular range.
Embodiments shown and described in detail herein are provided by way of example only; and the scope of the invention is not intended to be limited to the particular configurations, dimensionalities, and/or design details of these parts or elements included herein. In other words, a person skilled in the art would appreciate that design changes to these embodiments may be made and such that the resulting embodiments would be different than the embodiments disclosed herein, but would still be within the overall spirit of the present invention.
It should be understood that, unless stated otherwise herein, any of the features, characteristics, alternatives or modifications described regarding a particular embodiment herein may also be applied, used, or incorporated with any other embodiment described herein. Also, the drawing herein are not drawn to scale.
Although the invention has been described and illustrated with respect to exemplary embodiments thereof, the foregoing and various other additions and omissions may be made therein and thereto without departing from the spirit and scope of the present invention.
This application claims benefit to provisional patent application Ser. No. 61/263,572, filed 23 Nov. 2009, which is hereby incorporated by reference in its entirety.
Filing Document | Filing Date | Country | Kind | 371c Date |
---|---|---|---|---|
PCT/US2010/057860 | 11/23/2010 | WO | 00 | 9/24/2012 |
Publishing Document | Publishing Date | Country | Kind |
---|---|---|---|
WO2011/063408 | 5/26/2011 | WO | A |
Number | Name | Date | Kind |
---|---|---|---|
3555143 | Axen et al. | Jan 1971 | A |
3867517 | Ling | Feb 1975 | A |
3876376 | Bauman et al. | Apr 1975 | A |
3939350 | Kronick et al. | Feb 1976 | A |
4222744 | McConnell | Sep 1980 | A |
4254096 | Monthony et al. | Mar 1981 | A |
4368047 | Andrade et al. | Jan 1983 | A |
4425438 | Bauman et al. | Jan 1984 | A |
4447546 | Hirschfeld | May 1984 | A |
4517288 | Giegel et al. | May 1985 | A |
4690907 | Hibino et al. | Sep 1987 | A |
4716121 | Block et al. | Dec 1987 | A |
4717545 | Morris | Jan 1988 | A |
4797259 | Matkovich et al. | Jan 1989 | A |
4820490 | Morris | Apr 1989 | A |
4844869 | Glass | Jul 1989 | A |
4857453 | Ullman et al. | Aug 1989 | A |
4923819 | Fernandez et al. | May 1990 | A |
5004923 | Hillman et al. | Apr 1991 | A |
5009998 | Chow et al. | Apr 1991 | A |
5041181 | Brackett et al. | Aug 1991 | A |
5118608 | Layton et al. | Jun 1992 | A |
5164598 | Hillman et al. | Nov 1992 | A |
5296375 | Kricka et al. | Mar 1994 | A |
5302349 | Dandliker et al. | Apr 1994 | A |
5304487 | Wilding et al. | Apr 1994 | A |
5311275 | Taniguchi et al. | May 1994 | A |
5376252 | Ekstrom et al. | Dec 1994 | A |
5427946 | Kricka et al. | Jun 1995 | A |
5500350 | Baker et al. | Mar 1996 | A |
5508200 | Tiffany et al. | Apr 1996 | A |
5512151 | Hayamizu et al. | Apr 1996 | A |
5517778 | Simson | May 1996 | A |
5534328 | Ashmead et al. | Jul 1996 | A |
5593290 | Greisch et al. | Jan 1997 | A |
5622871 | May et al. | Apr 1997 | A |
5624850 | Kumar et al. | Apr 1997 | A |
5637469 | Wilding et al. | Jun 1997 | A |
5837546 | Allen et al. | Nov 1998 | A |
5842787 | Kopf-Sill et al. | Dec 1998 | A |
5856174 | Lipshutz et al. | Jan 1999 | A |
5861265 | Perry | Jan 1999 | A |
5866345 | Wilding et al. | Feb 1999 | A |
5876675 | Kennedy | Mar 1999 | A |
5882465 | McReynolds | Mar 1999 | A |
5885470 | Parce et al. | Mar 1999 | A |
5885527 | Buechler | Mar 1999 | A |
5886345 | Koster et al. | Mar 1999 | A |
5922591 | Anderson et al. | Jul 1999 | A |
5932799 | Moles | Aug 1999 | A |
5942443 | Parce et al. | Aug 1999 | A |
5965237 | Bruin et al. | Oct 1999 | A |
5976896 | Kumar et al. | Nov 1999 | A |
6008057 | Glass et al. | Dec 1999 | A |
6020209 | Narang et al. | Feb 2000 | A |
6046056 | Parce et al. | Apr 2000 | A |
6048498 | Kennedy | Apr 2000 | A |
6068751 | Neukermans | May 2000 | A |
6068752 | Dubrow et al. | May 2000 | A |
6073482 | Moles | Jun 2000 | A |
6082185 | Saaski | Jul 2000 | A |
6083763 | Balch | Jul 2000 | A |
6086740 | Kennedy | Jul 2000 | A |
6103537 | Ullman et al. | Aug 2000 | A |
6143152 | Simpson et al. | Nov 2000 | A |
6167910 | Chow | Jan 2001 | B1 |
6197595 | Anderson et al. | Mar 2001 | B1 |
6214560 | Yguerabide et al. | Apr 2001 | B1 |
6235241 | Catt et al. | May 2001 | B1 |
6238538 | Parce et al. | May 2001 | B1 |
6245296 | Ligler et al. | Jun 2001 | B1 |
6251343 | Dubrow et al. | Jun 2001 | B1 |
6267858 | Parce et al. | Jul 2001 | B1 |
6274337 | Parce et al. | Aug 2001 | B1 |
6293012 | Moles | Sep 2001 | B1 |
6306669 | Yano et al. | Oct 2001 | B1 |
6321791 | Chow | Nov 2001 | B1 |
6361958 | Shieh et al. | Mar 2002 | B1 |
6366924 | Parce | Apr 2002 | B1 |
6383748 | Carpay et al. | May 2002 | B1 |
6391622 | Knapp et al. | May 2002 | B1 |
6408878 | Unger et al. | Jun 2002 | B2 |
6479299 | Parce et al. | Nov 2002 | B1 |
6494230 | Chow | Dec 2002 | B2 |
6497155 | Feygin et al. | Dec 2002 | B1 |
6507989 | Bowden et al. | Jan 2003 | B1 |
6517778 | Kumar et al. | Feb 2003 | B1 |
6520753 | Grosjean et al. | Feb 2003 | B1 |
6524830 | Kopf-Sill et al. | Feb 2003 | B2 |
6532997 | Bedingham et al. | Mar 2003 | B1 |
6533914 | Liu | Mar 2003 | B1 |
6534013 | Kennedy | Mar 2003 | B1 |
6541213 | Weigl et al. | Apr 2003 | B1 |
6551841 | Wilding et al. | Apr 2003 | B1 |
6576478 | Wagner et al. | Jun 2003 | B1 |
6648015 | Chow | Nov 2003 | B1 |
6649358 | Parce et al. | Nov 2003 | B1 |
6649403 | McDevitt et al. | Nov 2003 | B1 |
6680206 | McDevitt et al. | Jan 2004 | B1 |
6719868 | Schueller et al. | Apr 2004 | B1 |
6729352 | O'Connor et al. | May 2004 | B2 |
6747285 | Schueller et al. | Jun 2004 | B2 |
6756019 | Dubrow et al. | Jun 2004 | B1 |
6767194 | Jeon et al. | Jul 2004 | B2 |
6767706 | Quake et al. | Jul 2004 | B2 |
6875619 | Blackburn | Apr 2005 | B2 |
6908737 | Ravkin et al. | Jun 2005 | B2 |
6908770 | McDevitt et al. | Jun 2005 | B1 |
6929030 | Unger et al. | Aug 2005 | B2 |
6960467 | Shieh et al. | Nov 2005 | B2 |
6994826 | Hasselbrink, Jr. et al. | Feb 2006 | B1 |
7005292 | Wilding et al. | Feb 2006 | B2 |
7018830 | Wilding et al. | Mar 2006 | B2 |
7028536 | Karp et al. | Apr 2006 | B2 |
7033476 | Lee et al. | Apr 2006 | B2 |
7040338 | Unger et al. | May 2006 | B2 |
7087181 | Schmidt et al. | Aug 2006 | B2 |
7122153 | Ho | Oct 2006 | B2 |
7125510 | Huang | Oct 2006 | B2 |
7128910 | Tucker et al. | Oct 2006 | B2 |
7143785 | Maerkl et al. | Dec 2006 | B2 |
7144616 | Unger et al. | Dec 2006 | B1 |
7164533 | Moon et al. | Jan 2007 | B2 |
7186383 | Webster et al. | Mar 2007 | B2 |
7189358 | Beach et al. | Mar 2007 | B2 |
7192559 | Chow et al. | Mar 2007 | B2 |
7192629 | Lammertink et al. | Mar 2007 | B2 |
7216671 | Unger et al. | May 2007 | B2 |
7238269 | Gason et al. | Jul 2007 | B2 |
7241421 | Webster et al. | Jul 2007 | B2 |
7250128 | Unger et al. | Jul 2007 | B2 |
7258837 | Yager et al. | Aug 2007 | B2 |
7285411 | Parce et al. | Oct 2007 | B1 |
7294503 | Quake et al. | Nov 2007 | B2 |
7326561 | Goodman et al. | Feb 2008 | B2 |
7343248 | Parce et al. | Mar 2008 | B2 |
7349158 | Moon et al. | Mar 2008 | B2 |
7351376 | Quake et al. | Apr 2008 | B1 |
7378280 | Quake et al. | May 2008 | B2 |
7396674 | Miyakawa et al. | Jul 2008 | B2 |
7399643 | Moon et al. | Jul 2008 | B2 |
7419639 | Osterfeld et al. | Sep 2008 | B2 |
7445926 | Mathies et al. | Nov 2008 | B2 |
7473562 | Van Beuningen et al. | Jan 2009 | B2 |
7476363 | Unger et al. | Jan 2009 | B2 |
7491552 | McDevitt et al. | Feb 2009 | B2 |
7507588 | Mehrpouyan et al. | Mar 2009 | B2 |
7622081 | Chou et al. | Nov 2009 | B2 |
7622083 | Amirkhanian et al. | Nov 2009 | B2 |
7682565 | Linton et al. | Mar 2010 | B2 |
7682817 | Cohen et al. | Mar 2010 | B2 |
7691333 | McBride et al. | Apr 2010 | B2 |
7695683 | Quan et al. | Apr 2010 | B2 |
7736890 | Sia et al. | Jun 2010 | B2 |
7736891 | Nelson et al. | Jun 2010 | B2 |
7745207 | Jovanovich et al. | Jun 2010 | B2 |
7754010 | Unger et al. | Jul 2010 | B2 |
7766033 | Mathies et al. | Aug 2010 | B2 |
7799553 | Mathies et al. | Sep 2010 | B2 |
7833708 | Enzelberger et al. | Nov 2010 | B2 |
7837946 | McBride et al. | Nov 2010 | B2 |
7843567 | Moon et al. | Nov 2010 | B2 |
7887750 | Blatt et al. | Feb 2011 | B2 |
7887753 | Quake et al. | Feb 2011 | B2 |
7892493 | Weekamp | Feb 2011 | B2 |
7919172 | Schueller et al. | Apr 2011 | B2 |
7935489 | O'Neill et al. | May 2011 | B2 |
7943089 | Yang et al. | May 2011 | B2 |
7947492 | Niehaus | May 2011 | B2 |
8049893 | Moon et al. | Nov 2011 | B2 |
8101403 | Yager et al. | Jan 2012 | B2 |
8124015 | Diercks et al. | Feb 2012 | B2 |
8129176 | Quake et al. | Mar 2012 | B2 |
8147774 | Hagiwara et al. | Apr 2012 | B2 |
8168139 | Manger et al. | May 2012 | B2 |
8211657 | Li et al. | Jul 2012 | B2 |
8236573 | Tokhtuev et al. | Aug 2012 | B2 |
8277759 | Sundberg et al. | Oct 2012 | B2 |
20010005489 | Roach et al. | Jun 2001 | A1 |
20020081744 | Chan et al. | Jun 2002 | A1 |
20020102742 | Parce et al. | Aug 2002 | A1 |
20020144738 | Unger et al. | Oct 2002 | A1 |
20020187560 | Pezzuto et al. | Dec 2002 | A1 |
20030012693 | Otillar et al. | Jan 2003 | A1 |
20030032191 | Hilson et al. | Feb 2003 | A1 |
20030054376 | Mullis et al. | Mar 2003 | A1 |
20030185713 | Leonard et al. | Oct 2003 | A1 |
20040101444 | Sommers et al. | May 2004 | A1 |
20040110199 | Montemagno et al. | Jun 2004 | A1 |
20040126875 | Putnam et al. | Jul 2004 | A1 |
20040189311 | Glezer et al. | Sep 2004 | A1 |
20040200909 | McMillan et al. | Oct 2004 | A1 |
20040219661 | Chen et al. | Nov 2004 | A1 |
20040228770 | Gandhi et al. | Nov 2004 | A1 |
20050098750 | Sobek | May 2005 | A1 |
20050100943 | Kambara et al. | May 2005 | A1 |
20050214173 | Facer et al. | Sep 2005 | A1 |
20050221385 | Nikiforov et al. | Oct 2005 | A1 |
20050266582 | Modlin et al. | Dec 2005 | A1 |
20060057576 | Paszkowski et al. | Mar 2006 | A1 |
20060063271 | Putnam et al. | Mar 2006 | A1 |
20060073484 | Mathies et al. | Apr 2006 | A1 |
20060076068 | Young et al. | Apr 2006 | A1 |
20060207877 | Schmidt et al. | Sep 2006 | A1 |
20060233668 | Resch-Genger et al. | Oct 2006 | A1 |
20060257956 | Basset et al. | Nov 2006 | A1 |
20060263818 | Scherer et al. | Nov 2006 | A1 |
20060263914 | Sando et al. | Nov 2006 | A1 |
20060289059 | Krylov et al. | Dec 2006 | A1 |
20070017633 | Tonkovich et al. | Jan 2007 | A1 |
20070149863 | Padmanabhan | Jun 2007 | A1 |
20070224084 | Holmes et al. | Sep 2007 | A1 |
20070248958 | Jovanovich et al. | Oct 2007 | A1 |
20080017512 | Bordunov et al. | Jan 2008 | A1 |
20080035499 | Weng | Feb 2008 | A1 |
20080131327 | Van Dam | Jun 2008 | A1 |
20080241858 | Metzger et al. | Oct 2008 | A1 |
20080280285 | Chen et al. | Nov 2008 | A1 |
20080311585 | Gao et al. | Dec 2008 | A1 |
20080311665 | Ryan et al. | Dec 2008 | A1 |
20090071833 | Gorfinkel et al. | Mar 2009 | A1 |
20090074623 | Park et al. | Mar 2009 | A1 |
20090087884 | Beerling et al. | Apr 2009 | A1 |
20090148933 | Battrell et al. | Jun 2009 | A1 |
20090181411 | Battrell et al. | Jul 2009 | A1 |
20090215158 | Sekizawa et al. | Aug 2009 | A1 |
20090253181 | Vangbo et al. | Oct 2009 | A1 |
20090257920 | Facer et al. | Oct 2009 | A1 |
20090325171 | Hirt et al. | Dec 2009 | A1 |
20090325276 | Battrell et al. | Dec 2009 | A1 |
20100101670 | Juncker et al. | Apr 2010 | A1 |
20100167384 | Clemmens et al. | Jul 2010 | A1 |
20100173394 | Colston, Jr. et al. | Jul 2010 | A1 |
20100186841 | Mukaddam et al. | Jul 2010 | A1 |
20100216248 | Wardlaw | Aug 2010 | A1 |
20100221814 | Asogawa et al. | Sep 2010 | A1 |
20100233791 | Sim et al. | Sep 2010 | A1 |
20100303687 | Blaga et al. | Dec 2010 | A1 |
20110008776 | Warthoe et al. | Jan 2011 | A1 |
20110020947 | Bedingham et al. | Jan 2011 | A1 |
20110105361 | Moon et al. | May 2011 | A1 |
20110195260 | Lee et al. | Aug 2011 | A1 |
20110262940 | Hisamoto et al. | Oct 2011 | A1 |
20110306081 | Szita et al. | Dec 2011 | A1 |
20120164036 | Stern et al. | Jun 2012 | A1 |
20120266986 | Wimberger-Friedl et al. | Oct 2012 | A1 |
Number | Date | Country |
---|---|---|
1189449 | Jun 1985 | CA |
3226407 | Jan 1984 | DE |
0401033 | Dec 1990 | EP |
1415788 | May 2004 | EP |
1404448 | Sep 2006 | EP |
1936382 | Jun 2008 | EP |
2284538 | Feb 2011 | EP |
2463666 | Jun 2012 | EP |
2155152 | Sep 1985 | GB |
94100467 | Jun 1996 | GR |
09288089 | Nov 1997 | JP |
2001-157855 | Jun 2001 | JP |
2003-507737 | Feb 2003 | JP |
2005-140681 | Jun 2005 | JP |
2007-516419 | Jun 2007 | JP |
122612 | Sep 2009 | RO |
9204613 | Mar 1992 | WO |
9737803 | Oct 1997 | WO |
9911754 | Mar 1999 | WO |
9944217 | Sep 1999 | WO |
0107889 | Feb 2001 | WO |
0114865 | Mar 2001 | WO |
03004160 | Jan 2003 | WO |
03042677 | May 2003 | WO |
2004000721 | Dec 2003 | WO |
2004034028 | Apr 2004 | WO |
2004041061 | May 2004 | WO |
2004059299 | Jul 2004 | WO |
2004061085 | Jul 2004 | WO |
2005066613 | Jul 2005 | WO |
2005107938 | Nov 2005 | WO |
2006071470 | Jul 2006 | WO |
2007021813 | Feb 2007 | WO |
2007032316 | Mar 2007 | WO |
2007033385 | Mar 2007 | WO |
2007044091 | Apr 2007 | WO |
2007092713 | Aug 2007 | WO |
2007093939 | Aug 2007 | WO |
2007106579 | Sep 2007 | WO |
2007117987 | Oct 2007 | WO |
2007136715 | Nov 2007 | WO |
2008032128 | Mar 2008 | WO |
2008043046 | Apr 2008 | WO |
2008075253 | Jun 2008 | WO |
2008089493 | Jul 2008 | WO |
2008115626 | Sep 2008 | WO |
2008154036 | Dec 2008 | WO |
2009012340 | Jan 2009 | WO |
2009029177 | Mar 2009 | WO |
2009088408 | Jul 2009 | WO |
2009105711 | Aug 2009 | WO |
2010017210 | Feb 2010 | WO |
2010027812 | Mar 2010 | WO |
2010057078 | May 2010 | WO |
2010077618 | Jul 2010 | WO |
2010148252 | Dec 2010 | WO |
2011040884 | Apr 2011 | WO |
2011053845 | May 2011 | WO |
2012129455 | Sep 2012 | WO |
Entry |
---|
Cooksey et al., “A vacuum manifold for rapid world-to-chip connectivity of complex PDMS microdevices,” Lab on a Chip, vol. 9, No. 9 (Jan. 1, 2009). |
Grover et al., “Teflon films for chemically-inert microfluidic valves and pumps,” Lab on a Chip, vol. 8, No. 6 (Jan. 1, 2008). |
Hicks, Jocelyn M., “Fluorescence Immunoassay,” from “Human Pathology”, vol. 15, No. 2, Feb. 1984, pp. 112-116 (5 pages). |
Fayram, Sandra L., “Fluorescence Immunoassay and Passive Latex Agglutination as Alternatives to Hemagglutination Inhibition for Determining Rubella Immune Status,” from “Journal of Clinical Microbiology,” vol. 17, No. 4, Apr. 3, 1983, pp. 685-688 (4 pages). |
Ozinskas, Alvydas J., “Principles of Fluorescence Immunoassay,” from “Topics in Fluorescence Spectroscopy, vol. 4: Probe Design and Chemical Sensing,” 1994, pp. 449-496 (48 pages). |
Japanese Office Action; JP 2012-540157; Aug. 6, 2013; 7 pp. |
Chaudhury and Whitesides, 1991,“Direct Measurement of Interfacial Interactions Between Semispherical Lenses and Flat Sheets of Poly(dimethylsiloxane) and Their Chemical Derivatives”, p. 1021: Interaction between Oxidized PDMS Surfaces. |
Delamarche et al, “Patterned Delivery of Immunoglobulins to Surfaces Using Microfluidic Networks”, Science, vol. 276, p. 779-781, (submitted Dec. 30, 1996). |
Duffy, et al, “Rapid Prototyping of Microfluidic Systems in Poly (dimethylsiloxane)”, Anal. Chem vol. 70, No. 23,1998, 4974-4984. |
Effenhauser et al, “Integrated Capillary Electrophoresis on Flexible Silcione Microdevices; Analysis of DNA . . . ”, Analytical Chemistry, vol. 69, No. 17, 3451-7. |
Folta et al, “Design, Fabrication and Testing of a Miniature Peristaltic Membrane Pump”, 1992, Technical Digest IEEE Solid-State Sensors and Actuators Workshop, pp. 186-189. |
Fujii et al., Bulk- and Surface-Modified Combinable PDMS Capillary Sensor Array as an Easy-to-Use Sensing Device with Enhanced Sensitivity to Elevated Concentrations of Multiple Serum Sample Components, Lab Chip 12:1522 (2012). |
Henares et al., “Current Development in Microfluidic Immunosensing Chip,” Analytica Chimica Acta 611:17-30 (2008). |
Henares et al., “Development of Single-Step Heterogenous Sandwich Capillary Immunosensor for Capillary-Assembled Microchip (CAs-CHIP) Integration,” Twelfth International Conference on Miniaturized Systems for Chemistry and Life Sciences, San Diego, California (Oct. 12-16, 2008). |
Henares et al., “Enzyme-Release Capillary as a Facile Enzymatic Biosensing Part for a Capillary-Assembled Microchip,” Analytical Sciences 25:1025-1028(Aug. 2009). |
Henares et al., “Multiple Enzyme Linked Immunosorbent Assay System on a Capillary-Assembled Microchip Integrating Valving and Immuno-Reaction Functions,” Analytica Chimica Acta 589:173-179 (2007). |
Henares et al., “Single-Drop Analysis of Various Proteases in a Cancer Cell Lysate Using a Capillary-Assembled Microchip,” Anal Bioanal Chem 391:2507-2512 (2008). |
Henares et al., “Single-Step ELISA Capillary Sensor Based on Surface-Bonded Glucose Oxidase, Antibody, and Physically-Adsorbed PEG Membrane Containing Peroxidase-Labeled Antibody,” Sensors and Actuators B 149:319-324 (2010). |
Hisamoto et al., “Capillary-Assembled Microchip as an On-Line Deproteinization Device for Capillary Electrophoresis,” Anal Bioanal Chem 386:733-738 (2006). |
Hisamoto et al., “Capillary-Assembled Microchip for Universal Integration of Various Chemical Functions onto a Single Microfluidic Device,” Anal. Chem. 76:3222-3228 (2004). |
Hisamoto et al., “Integration of Multiple-Ion-Sensing on a Capillary-Assembled Microchip,” Analytica Chimica Acta 556:164-170 (2006). |
Hisamoto et al., “Integration of Valving and Sensing on a Capillary-Assembled Microchip,” Anal. Chem. 77:2266-2271 (2005). |
Hosokawa, K. and Maeda, R., “A normally closed PDMS (polydimethylsiloxane) microvalve”, T.IEE Japan, vol. 120-E, No. 4, 2000. |
Hosokawa, K, and Maeda, R., “A pneumatically-actuated three-way microvalve fabricated with polydimethysiloxane using the membrane transfer technique”, J. Mickromecjh. Microeng. 10 (2000) 415-420. |
Lammerink, et al “Modular Concept for Fluid Handling Systems—A demonstrator Micro Analysis System”, 1996, Proc. IEEE Micro Electro Mechanical Systgems Workshop, San Diego CA, Feb. 1996, pp. 389-394. |
Macdonald and Whitesides, “Poly(dimethylsilocane) as a Material for Fabricating Microfluidic Devices”, 2002. |
Madou, Fundamentals of Microfabrication, CRC Press, 1997, pp. 382-394 especially p. 390. |
Shoji et al, “Microflow Devices and Systems”, 1994, J. Micromech. Microeng. 4 (1994) 157-171. |
Smits, “Piezoelectric Micropump with Three Valves Working Peristaltically”, 1990, Sensors and Actuators, A21-23 (1990) 203-206. |
Yacoub-George et al., “Automated 10-Channel Capillary Chip Immunodetector for Biological Agents Detection,” Biosensors and Bioelectronics 22:1368-1375 (2007). |
Supplementary European Search Report from corresponding European Appn. No. 10832371.8 dated Jul. 22, 2013. |
Supplementary European Search Report dated Nov. 5, 2014 for Application No. 12760266.2. |
European Communication dated Nov. 21, 2014 for Application No. 12760266.2. |
Number | Date | Country | |
---|---|---|---|
20130011859 A1 | Jan 2013 | US |
Number | Date | Country | |
---|---|---|---|
61263572 | Nov 2009 | US |